Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...

The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...

The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...

After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...

The trial will include patients with relapsed or refractory B-cell malignancies, including patients who have received prior CAR T-cell therapies.

NEW YORK – Nucs AI, a biotech using artificial intelligence to develop diagnostics and predictive imaging biomarkers in oncology, said on Tuesday it has partnered with Segmed, a real-world data ...

In an investigator-initiated trial, researchers will evaluate TPST-4003 in autoimmune disorders like myasthenia gravis and multiple sclerosis.

NEW YORK – The US Food and Drug Administration on Tuesday approved Celcuity's PI3K/AKT/mTOR inhibitor Revtorpyk (gedatolisib) with fulvestrant and with or without Pfizer's Ibrance (palbociclib) for ...

Primary care docs in Sweden diagnosed Alzheimer's with the same accuracy as dementia specialists when they had access to beta ...

Telix Pharmaceuticals has opened a new radiopharmaceutical manufacturing and treatment facility in Melbourne, Australia, the company announced Thursday. Telix said the integrated facility in Melbourne ...

ATR 1072, a small interfering RNA drug, is Atrium's first precision cardiology program to enter the clinic since its launch earlier this year.

The results presented at AAIC had been highly anticipated since Biogen said it would advance the drug despite missing a Phase ...